IAG Capital Partners

SixMap is an information technology company focused on enhancing cybersecurity through its external attack surface management platform. This technology is designed to detect and remediate vulnerabilities in network security policies by providing insights into the network's attack surfaces from an attacker's perspective. By enabling organizations to monitor their security posture effectively, SixMap assists in planning and managing transitions during cyber incidents, thereby reinforcing overall network security. The company's expertise lies in network security, software development, and cybersecurity, positioning it as a key player in the defense against cyber threats.

T-Robotics specializes in developing AI-driven robot programming platforms. Their core technology employs end-to-end neural networks and constraint-based programming to train robots, enabling them to learn and execute complex tasks using natural language commands. This innovative approach enhances robots' performance, reduces programming complexity, and ensures compatibility with major commercial robot brands.

Swave Photonics is a company that designs and markets advanced holographic chips utilizing proprietary diffractive photonics technology. Their innovative NanoPixel technology aims to deliver compact, lightweight, and high-resolution displays that enhance augmented reality experiences. By focusing on creating true holographic displays, Swave Photonics seeks to bridge the gap between digital content and the real world, empowering display manufacturers and content creators to visualize complex ideas and collaborate more effectively. The company's mission is to bring the metaverse to life, enabling immersive experiences that allow users to accomplish more in both personal and professional contexts.

Fluid Biomed is a medical device start-up specializing in the development of an innovative implantable dissolving stent aimed at treating brain aneurysms. Founded by a team of neurosurgeons, the company focuses on enhancing patient outcomes by offering a bio-absorbable polymer-based flow-diverting stent that gently redirects blood flow to facilitate the healing of weakened blood vessels. This advanced medical device is designed to minimize the need for invasive procedures, allowing physicians to efficiently and effectively treat patients while reducing the risk of stroke. Through its pioneering approach, Fluid Biomed is poised to contribute significantly to the field of neurosurgery and improve the quality of care for individuals with brain aneurysms.

Ayar Labs, Inc. specializes in the development of optical interconnect chiplets and lasers designed to enhance data transmission capabilities in various applications, including artificial intelligence, high-performance computing, cloud computing, telecommunications, and aerospace. The company's flagship product, TeraPHY, is a high-density electronic-photonic chiplet that utilizes a monolithic in-package optical I/O solution to facilitate high bandwidth and low latency connections. Ayar Labs aims to disrupt the conventional performance and efficiency standards in the semiconductor industry by providing power-efficient optical interconnects that replace traditional electrical I/O. This technology effectively addresses compute and bandwidth bottlenecks, particularly in the context of complex AI systems, enabling improved computing efficiency and performance while also reducing costs and power consumption. Founded in 2015, Ayar Labs is headquartered in Emeryville, California, with an additional office in Santa Clara.

Lightsynq specializes in developing optical quantum interconnects, which are crucial components for large-scale quantum computers. Their platform employs integrated diamond photonic circuits, designed to be compatible with diverse quantum computing architectures. This technology facilitates fault-tolerant operations, high-fidelity quantum communication, and cross-platform connectivity, thereby addressing the system scaling challenges faced by the quantum computing industry.

Enfabrica is a technology company that specializes in developing innovative hardware, software, and system solutions aimed at addressing performance bottlenecks in next-generation computing. The company focuses on designing advanced networking chips and converged memory fabric technologies tailored for artificial intelligence and accelerated computing workloads. Enfabrica's products are engineered to enhance system efficiency and scalability across a variety of infrastructure environments, including hyper-scale cloud, edge computing, and automotive applications. By leveraging cutting-edge technologies like compute express link, Enfabrica enables businesses to optimize resource utilization and support advanced AI and machine learning processing, thereby facilitating the deployment of high-performance information technology solutions.

Xscape Photonics specializes in the development of photonic chips aimed at enhancing bandwidth connections within high-performance computing systems and data centers. By leveraging photonics technology, the company creates scalable and energy-efficient solutions that support the demands of next-generation artificial intelligence, machine learning, and simulation hardware. Its photonic chips facilitate improved connections between various computing elements while minimizing power consumption, allowing clients to achieve faster and more efficient communication. Through its innovative approach, Xscape Photonics addresses the growing need for high-speed, sustainable connectivity in the evolving technological landscape.

MIRIS provides spatial material and allows users to communicate with digital content.

CroiValve Limited, founded in 2016 and based in Dublin, Ireland, specializes in the development of a medical device aimed at treating severe tricuspid regurgitation through a minimally invasive procedure. The company's innovative device allows for percutaneous delivery via a vein into the right heart, effectively sealing the gap between the native tricuspid valve leaflets. This approach restores proper valve function and prevents regurgitation, enabling healthcare professionals to address this condition in a safe, effective, and cost-efficient manner. CroiValve's solution is designed to be user-friendly, catering to a broad range of patients suffering from this serious heart issue.

VenoStent, Inc. is a clinical-stage tissue engineering company based in Nashville, Tennessee, with an additional office in Houston, Texas. Founded in 2017, the company specializes in developing bioresorbable smart polymers specifically designed for vascular surgery. Its flagship product, SelfWrap, is a perivascular wrap that functions as an external stent to enhance the success of dialysis procedures. SelfWrap addresses complications at the vein-artery or vein-graft junction by promoting outward vein growth and providing customized mechanical support, thereby reducing the risk of vein collapse and occlusion. This innovative approach utilizes a new class of shape-memory polymers that do not require sutures, ultimately improving surgical outcomes, reducing operation time, and minimizing infection risks for hemodialysis patients. VenoStent aims to significantly impact the approximately 5 million vascular surgeries conducted annually, enhancing the quality and longevity of life for chronic kidney disease patients.

DeepCure Inc. is a biotechnology company based in Boston, Massachusetts, specializing in artificial intelligence-driven drug discovery. Founded in 2018, DeepCure develops innovative solutions for small-molecule drug development, utilizing advanced deep learning algorithms and a proprietary database of chemical compounds. The company offers services such as De-novo Lead Discovery, which employs AI algorithms to assess potential drug candidates from a virtual library, and Artificial Intelligence-driven Lead Optimization, aimed at enhancing drug development processes. Additionally, DeepCure's platform includes a molecular database designed to maximize the diversity and synthesizability of chemical compounds. By integrating AI predictive modeling and a feedback loop, DeepCure focuses on creating effective therapeutics for unmet medical needs, ultimately aiming to expedite the development of novel precision medicines.

Celestial AI is a prominent artificial intelligence company that provides an advanced platform for users to efficiently create images, text, and presentations. Utilizing cutting-edge computer vision algorithms and natural language processing, the platform produces high-quality visual and textual content. Its intuitive design, combined with innovative features, facilitates easy content creation. Moreover, Celestial AI emphasizes intelligent data integration and prioritizes security, ensuring that users achieve impressive and reliable results.

RIOS, founded in 2018, is a technology company helping global customers automate their factories, warehouses, and supply chain operations by deploying a new class of dexterous AI-powered robots. RIOS robots handle hard-to-automate tasks, typically requiring human-level dexterity, in unstructured environments. RIOS is headquartered in Palo Alto, CA and has a pilot facility in San Carlos, CA. More information is available at www.rios.ai.

NLX is a company that offers an end-to-end enterprise AI platform designed to enhance customer experiences for large brands. Its no-code, multimodal conversation platform allows organizations to create, monitor, and analyze automated conversations, leveraging machine learning and artificial intelligence. This technology enables personalized customer interactions through automated chat, voice, and multimodal conversations, facilitating effective self-service experiences. NLX's platform is highly scalable, integrated, and accessible anytime and anywhere, empowering brands to manage conversational deployments across their entire enterprise effectively.

Jana Care, Inc. is a company focused on developing mobile diagnostic solutions for the screening, management, and monitoring of chronic diseases. Its flagship products include The Aina Device, a self-monitoring tool for patients, and The Aina Station, a diagnostic solution for clinics and hospitals. These devices facilitate a range of tests, such as blood glucose, HbA1c, lipid profiles, creatinine, and hemoglobin. Additionally, Jana Care offers The Habits Program, a twelve-week digital coaching initiative aimed at managing diabetes and pre-diabetes. Founded in 2011 and headquartered in Boston, Massachusetts, with an additional office in Bengaluru, India, Jana Care was inspired by a challenge from a physician-entrepreneur to create innovative health solutions for remote communities in India, ultimately evolving into one of the largest chronic disease screening programs globally.

Fantix is a company that specializes in a no-code platform designed to facilitate the development of AI models through a collaborative learning approach. By utilizing data abstraction, Fantix enables businesses to create robust machine learning models while preserving consumer privacy and maintaining business confidentiality. The platform transforms data locally, allowing small and medium-sized enterprises to gain insights without pooling user-level data. It compares data abstractions to identify meaningful overlaps between datasets, extracting aggregated and anonymous representations of the data while ensuring it remains encrypted and secure. This innovative approach empowers customers and businesses to analyze shared elements and discover valuable insights without compromising data privacy.

Enfabrica is a technology company that specializes in developing innovative hardware, software, and system solutions aimed at addressing performance bottlenecks in next-generation computing. The company focuses on designing advanced networking chips and converged memory fabric technologies tailored for artificial intelligence and accelerated computing workloads. Enfabrica's products are engineered to enhance system efficiency and scalability across a variety of infrastructure environments, including hyper-scale cloud, edge computing, and automotive applications. By leveraging cutting-edge technologies like compute express link, Enfabrica enables businesses to optimize resource utilization and support advanced AI and machine learning processing, thereby facilitating the deployment of high-performance information technology solutions.

Lucid Scientific, Inc. is a biotechnology tools company based in Atlanta, Georgia, specializing in the development of real-time cellular activity monitors for drug discovery and biological research. The company focuses on providing innovative systems that enable researchers in academic institutions and pharmaceutical companies to conduct continuous and non-invasive analysis of cellular behavior. Its flagship technology, RESIPHER, utilizes proprietary high-resolution optical oxygen sensors to measure oxygen consumption in standard multi-well plates. This tool streams real-time data to a user-friendly web application, allowing researchers to gain valuable insights into the cellular environment directly from the incubator, thereby enhancing the efficiency of cell culture experiments.

Swaybox Studios is an animation studio based in Shreveport, Louisiana, specializing in the development of innovative animation technology and processes for film and television production. The company focuses on integrating practical puppetry into its projects, aiming to present this art form in new and engaging ways. By combining traditional techniques with modern storytelling, Swaybox Studios seeks to create visually stunning and emotionally resonant narratives that maintain the nostalgic charm of puppetry. Their approach emphasizes dynamic expressiveness and a human touch, offering audiences a unique viewing experience that stands out in contemporary media.

VenoStent, Inc. is a clinical-stage tissue engineering company based in Nashville, Tennessee, with an additional office in Houston, Texas. Founded in 2017, the company specializes in developing bioresorbable smart polymers specifically designed for vascular surgery. Its flagship product, SelfWrap, is a perivascular wrap that functions as an external stent to enhance the success of dialysis procedures. SelfWrap addresses complications at the vein-artery or vein-graft junction by promoting outward vein growth and providing customized mechanical support, thereby reducing the risk of vein collapse and occlusion. This innovative approach utilizes a new class of shape-memory polymers that do not require sutures, ultimately improving surgical outcomes, reducing operation time, and minimizing infection risks for hemodialysis patients. VenoStent aims to significantly impact the approximately 5 million vascular surgeries conducted annually, enhancing the quality and longevity of life for chronic kidney disease patients.

Celestial AI is a machine learning accelerator focused on developing an optical interconnect technology platform designed for data centers and AI applications. By leveraging photonics, mixed-signal ASICs, and advanced packaging, the company aims to enhance computing performance sustainably. Its Photonic Fabric technology serves as the foundation for optically scalable and disaggregated data center computing and memory, facilitating significant advancements in AI. Celestial AI’s solutions enable clients to deliver improved hardware and software alternatives for deep learning and machine learning, ultimately driving profitable and sustainable business models.

Ayar Labs, Inc. specializes in the development of optical interconnect chiplets and lasers designed to enhance data transmission capabilities in various applications, including artificial intelligence, high-performance computing, cloud computing, telecommunications, and aerospace. The company's flagship product, TeraPHY, is a high-density electronic-photonic chiplet that utilizes a monolithic in-package optical I/O solution to facilitate high bandwidth and low latency connections. Ayar Labs aims to disrupt the conventional performance and efficiency standards in the semiconductor industry by providing power-efficient optical interconnects that replace traditional electrical I/O. This technology effectively addresses compute and bandwidth bottlenecks, particularly in the context of complex AI systems, enabling improved computing efficiency and performance while also reducing costs and power consumption. Founded in 2015, Ayar Labs is headquartered in Emeryville, California, with an additional office in Santa Clara.

Graphiant Inc. is a networking technology company founded in 2020 and headquartered in San Jose, California. It specializes in developing innovative solutions for wide area networks (WAN), particularly through its Graphiant Network Edge, a software-as-a-service platform. This technology facilitates connectivity across enterprise WANs, hybrid cloud environments, and network edges, enhancing the ability of businesses to connect with clients and partners efficiently. By integrating high-performance capabilities similar to multiprotocol label switching with the agility of internet-based systems, Graphiant's offerings empower network architects to create robust, enterprise-grade networks that keep pace with business demands.

Cognito Therapeutics, established in 2016 and headquartered in Newton Centre, Massachusetts, with additional locations in San Francisco and Boston, is a clinical-stage neurotechnology company. It specializes in developing non-invasive, device-based therapies to treat neurodegenerative diseases, with a primary focus on Alzheimer's disease. The company's innovative approach involves using induced brain wave oscillations to reactivate the immune system in the brain, aiming to reduce typical disease hallmarks such as amyloid plaques and tau tangles. Co-founded by MIT professors Li-Huei Tsai and Ed Boyden, Cognito's lead therapy is currently in a pivotal study for Alzheimer's, and has been recognized as a Breakthrough Device by the FDA.

NLX is a company that offers an end-to-end enterprise AI platform designed to enhance customer experiences for large brands. Its no-code, multimodal conversation platform allows organizations to create, monitor, and analyze automated conversations, leveraging machine learning and artificial intelligence. This technology enables personalized customer interactions through automated chat, voice, and multimodal conversations, facilitating effective self-service experiences. NLX's platform is highly scalable, integrated, and accessible anytime and anywhere, empowering brands to manage conversational deployments across their entire enterprise effectively.

Cornelis Networks, Inc. is a technology company based in Wayne, Pennsylvania, established in 2019. It specializes in developing high-performance fabrics tailored for scientific, commercial, and government sectors. By providing advanced networking products, Cornelis Networks aims to enhance computing capabilities, data analytics, and artificial intelligence workloads. The company’s solutions allow customers to effectively harness the computational power of multiple processing devices to address complex problems, thereby improving both outcomes and accuracy. With a focus on innovation, Cornelis Networks supports over 500 global installations across various industries, including government and academic institutions, striving to drive technological and scientific advancements.

UrbanFox is a technology company focused on safeguarding online merchants from payment fraud. It has developed a proprietary platform that employs generative AI and advanced behavioral analysis to detect and prevent various forms of complex fraud, including high-velocity payment and account scams. By utilizing large behavioral models, UrbanFox enables online retailers to identify and mitigate the risks associated with credit and purchase fraud, ultimately helping them to protect their revenue and maintain customer trust.

Leuko Labs, Inc., established in 2017 and headquartered in Boston, Massachusetts, specializes in the development of healthcare equipment. The company's primary product, PointCheck, is a non-invasive device designed to monitor and count white blood cells. This innovative technology allows for more frequent testing of immunosuppressed patients, such as those undergoing chemotherapy, enhancing their quality of life and clinical outcomes. The device is particularly beneficial as it eliminates the need for invasive blood draws and laboratory infrastructure, making it more accessible and convenient for patients.

GeneCentric Diagnostics is engaged in the development and commercialization of molecular diagnostic tests aimed at assisting oncologists and patients in cancer treatment. The company has established two primary platform technologies: The Lung Subtype Platform (LSP), which classifies lung cancer patients into specific subtypes to guide therapeutic choices, and the Hypoxia Signature, designed to identify patients likely to benefit from anti-angiogenesis therapies. The LSP has been licensed to Laboratory Corporation of America Holdings and is available as HistoPlusSM: Lung Cancer through its Integrated Oncology division. GeneCentric's innovative partnership model facilitates the translation of significant cancer research into diagnostics that are clinically adopted by pathologists and clinicians. Incorporated in 2011 and located in Durham, North Carolina, GeneCentric aims to enhance treatment outcomes by enabling more precise targeting of therapeutic compounds based on tumor biology.

Ordaos Bio is a biomedical research company based in Manhattan, New York, established in 2019. It focuses on revolutionizing drug discovery and development through the integration of artificial intelligence and biology. The company operates a human-enabled, machine-driven platform that facilitates the design of novel immunotherapies for oncology and chronic inflammatory diseases. By providing an AI-driven drug discovery pipeline, Ordaos Bio empowers researchers to develop treatments that are more effective and safer than conventional methods, thereby addressing significant challenges in medical research and enhancing therapeutic outcomes.

Elucid is a Boston-based biotechnology and medical technology company dedicated to enhancing cardiovascular diagnostic imaging through machine learning. The company has developed ElucidVivo, the first FDA-cleared software that evaluates plaque vulnerability from a single computed tomography angiography scan, aiding in the assessment of heart attack and stroke risks as well as informing treatment decisions. Elucid's technology enables objective quantification of arterial plaque extent and stability, providing a cost-effective and non-invasive means of capturing essential patient health information. In addition to its proprietary software, Elucid collaborates with pharmaceutical companies, healthcare providers, and research organizations to offer quantitative image analysis services, ultimately aiming to improve patient outcomes in cardiovascular care.

Ayar Labs, Inc. specializes in the development of optical interconnect chiplets and lasers designed to enhance data transmission capabilities in various applications, including artificial intelligence, high-performance computing, cloud computing, telecommunications, and aerospace. The company's flagship product, TeraPHY, is a high-density electronic-photonic chiplet that utilizes a monolithic in-package optical I/O solution to facilitate high bandwidth and low latency connections. Ayar Labs aims to disrupt the conventional performance and efficiency standards in the semiconductor industry by providing power-efficient optical interconnects that replace traditional electrical I/O. This technology effectively addresses compute and bandwidth bottlenecks, particularly in the context of complex AI systems, enabling improved computing efficiency and performance while also reducing costs and power consumption. Founded in 2015, Ayar Labs is headquartered in Emeryville, California, with an additional office in Santa Clara.

Lindy Biosciences is a development-stage company based in Durham, North Carolina, focused on producing protein-based therapeutic formulations. The company utilizes Microglassification technology, which gently removes most of the water from solutions of proteins or other biologics, creating solid, spherical, amorphous microbeads. These particles are stable and dense, making them suitable for various applications such as high-concentration suspensions, encapsulation for controlled release, and dry powder pulmonary delivery. Lindy Biosciences was incorporated in 2016 and specializes in formulations that enhance the long-term storage and delivery of protein therapeutics.

CaliberMind is a company that specializes in developing a B2B customer data platform designed for revenue marketers. The platform enables organizations to fully leverage their sales, marketing, and customer data through various features such as marketing attribution, engagement scoring, and insights into sales funnels and pipeline conversion points. Additionally, it provides tools for data integration, account engagement, and marketing workflow automation. By offering these capabilities, CaliberMind aims to enhance productivity, improve customer engagement, and ultimately drive revenue for its clients.

beatBread is an innovative music and finance company founded in 2020, designed to empower independent and unsigned artists to take charge of their careers while maintaining ownership of their music and decision-making autonomy. The company offers a unique artist financing platform that provides financial advances to musicians, which are repaid through a limited share of their revenues from streaming and airplay. By leveraging expertise in music, finance, artificial intelligence, and machine learning, beatBread aims to create new opportunities for artists and their managers, allowing them to select partners and advance their careers on their own terms.

Nanoligent is a biotech company that originated as a spin-off from Universitat Autònoma de Barcelona and Institut de Recerca de l'Hospital de la Santa Creu I Sant Pau. The company focuses on the design and development of targeted therapeutic biologics, particularly in the realm of nanotechnology-based anti-cancer treatments. Utilizing advanced protein engineering and nanobiotechnology, Nanoligent creates self-assembling protein nanoparticles that selectively target and kill metastatic cancer cells. This innovative approach aims to enhance treatment effectiveness while minimizing adverse effects, ultimately striving to improve patient outcomes by developing medicines that directly address the cells affected by disease.

Tethr is a company that specializes in providing an AI-driven communications intelligence platform designed to enhance enterprise decision-making by harnessing the Voice of the Customer. By analyzing customer interactions from various communication channels, including phone calls and chats, Tethr extracts valuable insights that help organizations understand customer sentiment and behavior. With a foundation built on over a decade of best-practice customer experience research, Tethr equips businesses to measure key performance indicators that affect sales, customer loyalty, operating costs, compliance, and risk management. The platform enables organizations to share these insights across their teams, fostering a culture of informed decision-making that directly impacts overall business performance.

GeneCentric Diagnostics is engaged in the development and commercialization of molecular diagnostic tests aimed at assisting oncologists and patients in cancer treatment. The company has established two primary platform technologies: The Lung Subtype Platform (LSP), which classifies lung cancer patients into specific subtypes to guide therapeutic choices, and the Hypoxia Signature, designed to identify patients likely to benefit from anti-angiogenesis therapies. The LSP has been licensed to Laboratory Corporation of America Holdings and is available as HistoPlusSM: Lung Cancer through its Integrated Oncology division. GeneCentric's innovative partnership model facilitates the translation of significant cancer research into diagnostics that are clinically adopted by pathologists and clinicians. Incorporated in 2011 and located in Durham, North Carolina, GeneCentric aims to enhance treatment outcomes by enabling more precise targeting of therapeutic compounds based on tumor biology.

First Ascent Biomedical is a biotechnology company focused on developing innovative solutions for oncology through the use of artificial intelligence. The company has created a drug prediction platform that utilizes therapy-resistant cell technologies to generate individualized treatment plans for cancer patients. By analyzing each patient's unique cancer cells and their responses to FDA-approved drugs, First Ascent Biomedical aims to provide affordable cancer treatment options while minimizing the risk of unsuccessful treatment regimens. Additionally, the company offers tools for drug development that enhance biomarker discovery and aid in the development of trial populations, thereby facilitating advancements in cancer care and improving patient outcomes.

New View Surgical, Inc. is an innovative medical device company based in Boston, Massachusetts, focused on the development and commercialization of the VisionPort technology. Founded in 2009, the company has created a novel surgical imaging and access system designed specifically for minimally invasive surgery. The VisionPort system consolidates four essential surgical devices—laparoscope, camera, light source, and access port—into a single, user-friendly, disposable device. This integration provides surgeons with enhanced control over both visualization and instrumentation, aiming to address various unmet needs in the market. By simplifying the surgical process, New View Surgical seeks to deliver significant clinical and economic advantages to operating rooms worldwide.

UpGuard Inc. is a cybersecurity company that provides a comprehensive platform aimed at assessing and managing cyber risks. Founded in 2012 and headquartered in Mountain View, California, UpGuard offers tools such as the CyberSecurity Threat Assessment Report (CSTAR), which evaluates an organization's IT infrastructure and assigns a risk score that reflects potential vulnerabilities. Its solutions include integrity monitoring, configuration differencing, and advanced vulnerability analytics, which help clients identify security gaps and streamline compliance efforts. Additionally, UpGuard's platform automates the documentation of configuration states for servers and network devices, facilitating better risk assessment and management. The company's technology is utilized by numerous organizations, including major corporations, to enhance their security posture, improve DevOps initiatives, and support cybersecurity insurance procurement. UpGuard was previously known as ScriptRock Inc. before rebranding in January 2016.

Elucid is a Boston-based biotechnology and medical technology company dedicated to enhancing cardiovascular diagnostic imaging through machine learning. The company has developed ElucidVivo, the first FDA-cleared software that evaluates plaque vulnerability from a single computed tomography angiography scan, aiding in the assessment of heart attack and stroke risks as well as informing treatment decisions. Elucid's technology enables objective quantification of arterial plaque extent and stability, providing a cost-effective and non-invasive means of capturing essential patient health information. In addition to its proprietary software, Elucid collaborates with pharmaceutical companies, healthcare providers, and research organizations to offer quantitative image analysis services, ultimately aiming to improve patient outcomes in cardiovascular care.

VenoStent, Inc. is a clinical-stage tissue engineering company based in Nashville, Tennessee, with an additional office in Houston, Texas. Founded in 2017, the company specializes in developing bioresorbable smart polymers specifically designed for vascular surgery. Its flagship product, SelfWrap, is a perivascular wrap that functions as an external stent to enhance the success of dialysis procedures. SelfWrap addresses complications at the vein-artery or vein-graft junction by promoting outward vein growth and providing customized mechanical support, thereby reducing the risk of vein collapse and occlusion. This innovative approach utilizes a new class of shape-memory polymers that do not require sutures, ultimately improving surgical outcomes, reducing operation time, and minimizing infection risks for hemodialysis patients. VenoStent aims to significantly impact the approximately 5 million vascular surgeries conducted annually, enhancing the quality and longevity of life for chronic kidney disease patients.

OpenDrives LLC is a company that specializes in developing high-performance network-attached storage (NAS) solutions tailored for industries reliant on high-resolution video and imaging, such as broadcast, video editing, and visual effects. Founded in 2015 and based in Culver City, California, OpenDrives offers a range of products including Avalanche, an all-flash storage system designed for demanding workflows; Spectre, a hybrid storage system that adapts to changing production needs; and Ridgeview, a high-density solution for nearline and active archiving. Additionally, the company provides OPUS, an enterprise-grade management platform aimed at enhancing operational efficiency in the media and entertainment sectors. OpenDrives focuses on enabling clients to manage large volumes of data with high concurrency, ensuring optimal performance and seamless workflows.

Coagulo Medical Technologies, based in Auburndale, Massachusetts, specializes in developing innovative point-of-care testing platforms for managing coagulation disorders. Their portable and connected precision-medicine system detects, identifies, and quantifies the effects of all anticoagulants in whole blood, providing healthcare providers with actionable results to improve patient outcomes.

CoreCare, Inc. is a technology company based in Fort Worth, Texas, that specializes in an artificial intelligence-driven software as a service (SaaS) platform designed for the senior living industry. Founded in 2019, CoreCare's platform connects provider and payor information systems, effectively standardizing and aggregating data to resolve inconsistencies. Its flagship product, CoreAccess, streamlines the billing process for healthcare providers, facilitating the preparation, submission, reconciliation, and reconsideration of reimbursements. By enhancing operational workflows, CoreCare not only increases admissions and optimizes reimbursement rates but also reduces administrative burdens for post-acute and long-term care providers. The platform promotes collaborative revenue management, empowering teams to work efficiently and collaboratively while providing management with valuable insights into performance. With a growing client base of over 1,000 locations nationwide, CoreCare is redefining operational efficiency in the long-term care sector.

Obsidio, Inc. is a medical device company based in Solana Beach, California, founded in 2018. The company specializes in developing shear-thinning hydrogel biomaterial technology, which is utilized to create therapeutic devices and universal gel embolization materials. This innovative technology allows for minimally invasive embolization procedures to effectively stop unwanted blood flow in vessels throughout the body. Obsidio's products are designed to address a variety of medical issues, including hemorrhage, aneurysms, and cancers, by providing targeted control of bleeding and occlusion of blood vessels. The company's biomaterial platform is applicable in interventional radiology and oncology, enabling precise and durable treatment solutions.

Zopa is a UK-based online marketplace lending platform, established in 2004, that connects individuals seeking unsecured loans with investors, both private and institutional. The platform offers various loan types, including car loans, debt consolidation, home improvement, and wedding loans, as well as peer-to-peer investment opportunities. Zopa facilitates these transactions, charging a fixed fee for borrowers and a 1% annual fee for lenders. The platform mitigates risk by enforcing monthly repayments, legal contracts, and diversifying investments. Zopa also provides an app for users to manage their loans, credit cards, savings, and monitor their credit scores. The company has received numerous awards for its innovative services and customer service.

Tethr is a company that specializes in providing an AI-driven communications intelligence platform designed to enhance enterprise decision-making by harnessing the Voice of the Customer. By analyzing customer interactions from various communication channels, including phone calls and chats, Tethr extracts valuable insights that help organizations understand customer sentiment and behavior. With a foundation built on over a decade of best-practice customer experience research, Tethr equips businesses to measure key performance indicators that affect sales, customer loyalty, operating costs, compliance, and risk management. The platform enables organizations to share these insights across their teams, fostering a culture of informed decision-making that directly impacts overall business performance.

Lindy Biosciences is a development-stage company based in Durham, North Carolina, focused on producing protein-based therapeutic formulations. The company utilizes Microglassification technology, which gently removes most of the water from solutions of proteins or other biologics, creating solid, spherical, amorphous microbeads. These particles are stable and dense, making them suitable for various applications such as high-concentration suspensions, encapsulation for controlled release, and dry powder pulmonary delivery. Lindy Biosciences was incorporated in 2016 and specializes in formulations that enhance the long-term storage and delivery of protein therapeutics.

Grips Intelligence is an e-commerce market research platform that specializes in transforming data from websites into actionable insights for manufacturers, retailers, and investors. By leveraging advanced machine learning technology, Grips Intelligence enables businesses to optimize their online sales performance through functions such as website categorization and cross-domain product mapping. The platform provides valuable transactional intelligence data, helping thousands of companies worldwide identify growth opportunities and enhance their performance in the competitive e-commerce landscape. With its focus on delivering data-driven insights, Grips Intelligence supports its clients in making informed decisions that unlock their full potential in the market.

Path Ex, Inc. is a Nashville, Tennessee-based company founded in 2017 that specializes in the manufacture of extracorporeal blood cleansing equipment. The company has developed a proprietary technology aimed at selectively separating and capturing bacteria and toxins from human blood, specifically for the treatment of sepsis, a critical condition often linked to blood-borne infections. Unlike conventional methods that rely on antibiotics to combat infections, Path Ex's innovative approach focuses on removing intact bacteria from the bloodstream, making it effective against various bacteria types and drug-resistant strains. This technology has the potential to significantly improve patient outcomes by reducing diagnostic times, lowering treatment costs, decreasing readmission rates, and ultimately decreasing sepsis-related mortality.

Graphiant Inc. is a networking technology company founded in 2020 and headquartered in San Jose, California. It specializes in developing innovative solutions for wide area networks (WAN), particularly through its Graphiant Network Edge, a software-as-a-service platform. This technology facilitates connectivity across enterprise WANs, hybrid cloud environments, and network edges, enhancing the ability of businesses to connect with clients and partners efficiently. By integrating high-performance capabilities similar to multiprotocol label switching with the agility of internet-based systems, Graphiant's offerings empower network architects to create robust, enterprise-grade networks that keep pace with business demands.